Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.

ACTA GASTRO-ENTEROLOGICA BELGICA, cilt.75, sa.2, ss.240-244, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 75 Sayı: 2
  • Basım Tarihi: 2012
  • Dergi Adı: ACTA GASTRO-ENTEROLOGICA BELGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.240-244
  • Anahtar Kelimeler: sitagliptin, diabetes, nonalcoholic steatohepatitis, dipeptidyl peptidase-IV inhibitor, DPPIV, DIPEPTIDYL-PEPTIDASE-IV, FATTY LIVER-DISEASE, GLYCEMIC CONTROL, DPP-IV, DISTURBANCES, VILDAGLIPTIN, INHIBITION, PREVENTS, THERAPY, DIET
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

Background & Aims : Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.